In yesterday’s Wall Street session, Bausch + Lomb Corporation (NYSE:BLCO) shares traded at $20.77, up 3.49% from the previous session.
As of this writing, 14 analysts cover Bausch + Lomb Corporation (NYSE:BLCO). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $24.00 and a low of $17.00, we find $20.67. Given the previous closing price of $20.07, this indicates a potential upside of 2.99 percent. BLCO stock price is now 12.26% away from the 50-day moving average and 24.53% away from the 200-day moving average. The market capitalization of the company currently stands at $7.35B.
There are 6 analysts who have given it a hold rating, whereas 7 have given it a buy rating. Brokers who have rated the stock have averaged $20.61 as their price target over the next twelve months.
A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BLCO stock. A new stake in Bausch + Lomb Corporation shares was purchased by NORGES BANK during the first quarter worth $57,064,000. VICTORY CAPITAL MANAGEMENT INC invested $15,679,000 in shares of BLCO during the first quarter. In the first quarter, STIFEL FINANCIAL CORP acquired a new stake in Bausch + Lomb Corporation valued at approximately $3,152,000. CAPSTONE INVESTMENT ADVISORS, LLC acquired a new stake in BLCO for approximately $588,000. RENAISSANCE TECHNOLOGIES LLC purchased a new stake in BLCO valued at around $532,000 in the second quarter.
Monday morning saw Bausch + Lomb Corporation (NYSE: BLCO) opened at $20.07. During the past 12 months, Bausch + Lomb Corporation has had a low of $12.20 and a high of $21.95. As of last week, the company has a debt-to-equity ratio of 0.36, a current ratio of 1.70, and a quick ratio of 1.20. The fifty day moving average price for BLCO is $18.50 and a two-hundred day moving average price translates $16.68 for the stock.
The latest earnings results from Bausch + Lomb Corporation (NYSE: BLCO) was released for Mar, 2023. According to the Medical Instruments & Supplies Company, earnings per share came in at $0.13, inline with analysts’ expectations of $0.13. This compares to $0.07 EPS in the same period last year. The net profit margin was -2.70% and return on equity was -1.50% for BLCO. The company reported revenue of $931.0 million for the quarter, compared to $889.0 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 4.72 percent. For the current quarter, analysts expect BLCO to generate $1.28B in revenue.
Bausch + Lomb Corporation(BLCO) Company Profile
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products for therapeutic use, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, dry eye, and redness relief. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.
